Skip to main content

Table 1 The Cancer Genome Atlas lists the clinicopathological traits of groups with high and low FDC-SP expression (TCGA)

From: FDC-SP as a diagnostic and prognostic biomarker and modulates immune infiltrates in renal cell carcinoma

Characteristics

Low expression of FDCSP

High expression of FDCSP

p value

n

266

266

 

Pathologic T stage, n (%)

0.006

 T1

153 (28.8%)

119 (22.4%)

 

 T2

36 (6.8%)

33 (6.2%)

 

 T3

74 (13.9%)

106 (19.9%)

 

 T4

3 (0.6%)

8 (1.5%)

 

Histologic grade, n (%)

 < 0.001

 G1

10 (1.9%)

4 (0.8%)

 

 G2

122 (23.3%)

106 (20.2%)

 

 G3

109 (20.8%)

97 (18.5%)

 

 G4

21 (4%)

55 (10.5%)

 

Pathologic stage, n (%)

0.002

 Stage I

150 (28.4%)

116 (21.9%)

 

 Stage II

30 (5.7%)

27 (5.1%)

 

 Stage III

59 (11.2%)

64 (12.1%)

 

 Stage IV

27 (5.1%)

56 (10.6%)

 

Pathologic N stage, n (%)

0.036

 N0

125 (48.8%)

115 (44.9%)

 

 N1

4 (1.6%)

12 (4.7%)

 

Pathologic M stage, n (%)

 < 0.001

 M0

224 (44.8%)

197 (39.4%)

 

 M1

24 (4.8%)

55 (11%)

 

OS event, n (%)

 < 0.001

 Alive

201 (37.8%)

156 (29.3%)

 

 Dead

65 (12.2%)

110 (20.7%)

 

Age, n (%)

0.386

 <  = 60

137 (25.8%)

127 (23.9%)

 

 > 60

129 (24.2%)

139 (26.1%)

 

Gender, n (%)

0.318

 Female

88 (16.5%)

99 (18.6%)

 

 Male

178 (33.5%)

167 (31.4%)

 

Laterality, n (%)

0.830

 Left

124 (23.4%)

126 (23.7%)

 

 Right

142 (26.7%)

139 (26.2%)